14 results on '"Dinyari P"'
Search Results
2. Computational study on stereoselective synthesis of substituted 1H-tetrazoles via a click reaction: DFT and QTAIM approaches.
- Author
-
Hosseinnejad, Tayebeh and Dinyari, Mahnaz
- Subjects
STEREOSELECTIVE reactions ,TETRAZOLES ,CLICK chemistry ,HETEROCYCLIC compounds synthesis ,DENSITY functional theory ,ACRYLONITRILE - Abstract
In the present research, the observed stereoselectivity in catalyst-free click synthesis of 1H-tetrazole-5-yl-acrylonitriles has been modeled by means of density functional theory (DFT) employed to investigate the structural and thermochemical aspects of this synthesis in the gas and solution phases. Comparison of our calculated structural parameters of the title compound with the available X-ray crystallographical data demonstrated a reliable agreement. Then, the effect of five different solvents, benzene, chloroform, ethanol, methanol and water was examined via polarized continuum model (PCM) calculations, showing a significant decrease in the computed values of the reaction enthalpy and free energy changes compared with the gas phase results and also the thermodynamical preference in using water solution in comparison with nonpolar solvents such as benzene and other protic and aprotic polar ones such as methanol, ethanol and chloroform that is in confirmation with the experimental observations. Additionally, we have concentrated on origins of the observed stereoselectivity by means of topological electronic indices via quantum theory of atoms in molecule (QTAIM) approach. In this respect, we have assessed the variation of electronic density and its Laplacian at some selected bond critical points of stereoisomer products, their corresponded transition states and intermediate and also construe the experimental elucidations. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. Composite Optical Microcavity of Diamond Nanopillar and Silica Microsphere.
- Author
-
Mats Larsson, Khodadad Nima Dinyari, and Hailin Wang
- Published
- 2009
- Full Text
- View/download PDF
4. ALEMTUZUMAB INDUCTION AND TAC/MMF MAINTENANCE SUBSTANTIALLY IMPROVES LONG TERM INSULIN INDEPENDENCE RATES AFTER CLINICAL ISLET TRANSPLANTATION, AND STRONGLY SUPPRESSES BOTH AUTO AND ALLOREACTIVITY.
- Author
-
Shapiro, A. M.j., Toso, C., Koh, A., Calne, S. R., Kin, T., O'gorman, D., Malcolm, A., Dinyari, P., Imes, S., Owen, R., Kneteman, N. M., Bigam, D., Senior, P., and Roep, B.
- Published
- 2010
- Full Text
- View/download PDF
5. A gulf of difference.
- Author
-
Dinyari K
- Published
- 2007
6. Comparison of metabolic responses to the mixed meal tolerance test vs the oral glucose tolerance test after successful clinical islet transplantation.
- Author
-
Forbes S, Lam A, Koh A, Imes S, Dinyari P, Malcolm AJ, Shapiro AMJ, and Senior PA
- Subjects
- Adult, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, ROC Curve, Diabetes Mellitus, Type 1 surgery, Fasting, Glucose Tolerance Test methods, Graft Survival, Islets of Langerhans Transplantation methods, Meals, Postprandial Period
- Abstract
Following islet transplantation, mixed meal tolerance tests (MMTs) are routinely utilized to assess graft function, but how the 90-minute MMTT glucose value relates to a 120-minute glucose concentration of ≥11.1 mmol/L used to diagnose diabetes following a standardized 75 g-OGTT, is not known. We examined this relationship further. Thirteen subjects with Type 1 diabetes and stable transplant grafts, not on exogenous insulin with HbA1c < 7% (53 mmol/mol), were studied on 17 occasions with paired OGTTs and MMTTs. Receiver operating characteristic (ROC) curves were constructed to derive the 90-minute MMTT glucose threshold associated with a 120-minute glucose concentration following a 75 g-OGTT (OGTT
120 ) ≥11.1 mmol/L and their diagnostic accuracy. Studies with OGTT120 ≥11.1 mmol/L (n = 5) had diminished C-peptide: glucose, greater integrated glucose and diminished insulin: glucose area under the curve (AUC) ratios (0-120 minutes) and disposition indices; all P < .05, contrasting with MMTTs where no difference in the 90-minute glucose concentrations, C-peptide:glucose, integrated glucose, C-peptide and C-peptide: glucose AUCs (0-90 minutes) was seen; all P > .05. A 90-minute MMTT glucose concentration ≥8.0 mmol/L demonstrated a sensitivity and specificity of ≥80% for the diagnosis of OGTT120 ≥11.1 mmol/L; area under ROC curve (mean ± SEM) 73 ± 13%. A 90-minute MMTT glucose ≥8.0 mmol/L, identifies islet transplant recipients who may require closer monitoring for graft dysfunction., (© 2018 The Authors. Clinical Transplantation Published by John Wiley & Sons Ltd.)- Published
- 2018
- Full Text
- View/download PDF
7. Purified Human Pancreatic Islets, CIT Culture Media with Lisofylline or Exenatide.
- Author
-
Ansite J, Balamurugan AN, Barbaro B, Battle J, Brandhorst D, Cano J, Chen X, Deng S, Feddersen D, Friberg A, Gilmore T, Goldstein JS, Holbrook E, Khan A, Kin T, Lei J, Linetsky E, Liu C, Luo X, McElvaney K, Min Z, Moreno J, O'Gorman D, Papas KK, Putz G, Ricordi C, Szot G, Templeton T, Wang L, Wilhelm JJ, Willits J, Wilson T, Zhang X, Avila J, Begley B, Cano J, Carpentier S, Holbrook E, Hutchinson J, Larsen CP, Moreno J, Sears M, Turgeon NA, Webster D, Deng S, Lei J, Markmann JF, Bridges ND, Czarniecki CW, Goldstein JS, Putz G, Templeton T, Wilson T, Eggerman TL, Al-Saden P, Battle J, Chen X, Hecyk A, Kissler H, Luo X, Molitch M, Monson N, Stuart E, Wallia A, Wang L, Wang S, Zhang X, Bigam D, Campbell P, Dinyari P, Kin T, Kneteman N, Lyon J, Malcolm A, O'Gorman D, Onderka C, Owen R, Pawlick R, Richer B, Rosichuk S, Sarman D, Schroeder A, Senior PA, Shapiro AMJ, Toth L, Toth V, Zhai W, Johnson K, McElroy J, Posselt AM, Ramos M, Rojas T, Stock PG, Szot G, Barbaro B, Martellotto J, Oberholzer J, Qi M, Wang Y, Bayman L, Chaloner K, Clarke W, Dillon JS, Diltz C, Doelle GC, Ecklund D, Feddersen D, Foster E, Hunsicker LG, Jasperson C, Lafontant DE, McElvaney K, Neill-Hudson T, Nollen D, Qidwai J, Riss H, Schwieger T, Willits J, Yankey J, Alejandro R, Corrales AC, Faradji R, Froud T, Garcia AA, Herrada E, Ichii H, Inverardi L, Kenyon N, Khan A, Linetsky E, Montelongo J, Peixoto E, Peterson K, Ricordi C, Szust J, Wang X, Abdulla MH, Ansite J, Balamurugan AN, Bellin MD, Brandenburg M, Gilmore T, Harmon JV, Hering BJ, Kandaswamy R, Loganathan G, Mueller K, Papas KK, Pedersen J, Wilhelm JJ, Witson J, Dalton-Bakes C, Fu H, Kamoun M, Kearns J, Li Y, Liu C, Luning-Prak E, Luo Y, Markmann E, Min Z, Naji A, Palanjian M, Rickels M, Shlansky-Goldberg R, Vivek K, Ziaie AS, Fernandez L, Kaufman DB, Zitur L, Brandhorst D, Friberg A, and Korsgren O
- Published
- 2017
8. Soluble donor DNA and islet injury after transplantation.
- Author
-
Gadi VK, Nelson JL, Guthrie KA, Anderson CC, Boespflug ND, Redinger JW, Paul B, Dinyari P, and Shapiro AM
- Subjects
- Adult, Aged, Biomarkers blood, DNA genetics, Diabetes Mellitus, Type 1 surgery, Female, Genotype, HLA Antigens genetics, Humans, Male, Middle Aged, Postoperative Complications etiology, Prospective Studies, Solubility, DNA blood, Islets of Langerhans injuries, Islets of Langerhans Transplantation adverse effects, Tissue Donors
- Abstract
Introduction: A large proportion of clinical islet transplant recipients fail to initially achieve or sustain meaningful independence from exogenous insulin use. We hypothesized that immediate allograft injury is a key constraint on independence from exogenous insulin use., Methods: Standard human leukocyte antigen genotyping was reviewed to identify nonshared polymorphisms between 21 prospectively recruited islet transplant recipients from a single institution and their respective donors. Human leukocyte antigen polymorphism-specific quantitative polymerase chain reaction was used to quantify donor DNA shed into blood by injured islets from serial sera acquired over the first 10 days postprocedure and examined for correlation with achievement of insulin independence., Results: Nearly fourfold higher serum concentrations of donor DNA were detected in subjects whose grafts failed to generate insulin independence. The median for the average area under the curve in recipients who did and did not achieve insulin independence was 12 (range, 1-61) and 45 (range, 14-255) donor genome equivalents (gEq)-day/mL (p=0.03), respectively., Conclusions: These findings represent the first direct testing of allograft injury in humans undergoing islet cell transplantation. Injury to donor islets very soon after transplantation may represent an important barrier to achieving insulin independence other than adaptive immune responses targeting allografts at later times. In addition, soluble donor DNA merits further development as a quantifiable biomarker to evaluate new interventions aimed at mitigating immediate islet injury.
- Published
- 2011
- Full Text
- View/download PDF
9. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success.
- Author
-
Koh A, Senior P, Salam A, Kin T, Imes S, Dinyari P, Malcolm A, Toso C, Nilsson B, Korsgren O, and Shapiro AM
- Subjects
- Adult, Anticoagulants administration & dosage, Anticoagulants therapeutic use, Antithrombins analysis, Blood Glucose metabolism, Diabetes Mellitus, Type 1 blood, Drug Administration Schedule, Female, Heparin, Low-Molecular-Weight administration & dosage, Humans, Hypoglycemic Agents administration & dosage, Hypoglycemic Agents therapeutic use, Insulin administration & dosage, Male, Middle Aged, Multivariate Analysis, Patient Selection, Regression Analysis, Retrospective Studies, Thrombin analysis, Treatment Outcome, Diabetes Mellitus, Type 1 surgery, Heparin, Low-Molecular-Weight therapeutic use, Insulin therapeutic use, Islets of Langerhans Transplantation physiology, Perioperative Care methods, Tissue Donors statistics & numerical data
- Abstract
Background: Successful islet transplantation can result in insulin independence in many patients with type 1 diabetes mellitus, but it often requires more than one islet infusion. The ability to achieve insulin independence with a single donor is an important goal in clinical islet transplantation due to the limited organ supply., Methods: We examined factors that may be associated with insulin independence after islet transplantation with islets from a single donor, using univariate and multivariate analysis., Results: Thirteen of 85 (15.3%) achieved insulin independence after single-donor islet transplantation. Using multivariate analysis, only the use of insulin and heparin infusions peritransplant was a significant factor associated with insulin independence, with an adjusted odds ratio of 8.6 (95% confidence interval 2.0-37.0). Patients who had received insulin and heparin infusions peritransplant had greater indices of islet engraftment and a greater reduction in insulin use (80.1% + or - 4.3% vs. 54.2% + or - 2.8%, P<0.001) even if insulin independence was not achieved., Conclusions: Peritransplant intensive insulin and heparin enhances islet transplantation outcomes likely related in part to mitigation of the effects of the instant blood-mediated inflammatory reaction, combined with islet rest and avoidance of inflammation. It would be important to further investigate the effects of peritransplant insulin and heparin infusions on islet engraftment.
- Published
- 2010
- Full Text
- View/download PDF
10. Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients.
- Author
-
Koh A, Imes S, Kin T, Dinyari P, Malcolm A, Toso C, Shapiro AM, and Senior P
- Subjects
- Antilymphocyte Serum therapeutic use, Blood Glucose metabolism, C-Peptide blood, Drug Therapy, Combination, Etanercept, Female, Glycated Hemoglobin metabolism, Humans, Hyperglycemia drug therapy, Hyperglycemia epidemiology, Immunoglobulin G therapeutic use, Immunosuppressive Agents therapeutic use, Islets of Langerhans Transplantation immunology, Male, Postoperative Complications blood, Postoperative Complications drug therapy, Receptors, Tumor Necrosis Factor therapeutic use, Sirolimus therapeutic use, Tacrolimus therapeutic use, Hypoglycemic Agents therapeutic use, Insulin therapeutic use, Islets of Langerhans Transplantation methods
- Abstract
Background: The ability of supplemental islet infusions (SII) to restore insulin independence in islet transplant recipients with graft dysfunction has been attributed to the coadministration of exenatide. However, improving islet transplant outcomes could explain the success of SII. We aimed to determine the effect on islet graft function and insulin independence of SII using these new protocols, without the use of exenatide., Methods: Seventeen islet transplant recipients underwent SIIs after developing graft dysfunction requiring insulin use. For induction therapy, four subjects received daclizumab induction therapy, whereas 13 subjects received thymoglobulin and etanercept. Maintenance immunosuppression consisted of sirolimus+tacrolimus or tacrolimus+cellcept., Results: SII was performed 49.3+/-4.8 months (mean+/-SEM) after the preceding islet transplant. Subjects received significantly lower islet mass with their SII compared with initial transplant(s) (6076+/-492 vs. 9071+/-796 IEQ/kg; P=0.003). Fifteen of the 17 subjects (88.2%) became insulin independent 2.4+/-0.5 months after SII. Insulin-independent duration after SII exceeded that of the initial transplant(s) (24.8+/-2.2 vs. 14.2+/-2.6 months by Kaplan-Meier analysis, P=0.009). Subjects show improved glycemic control after SII (HbA1c 7.0%+/-0.2% pre-SII vs. 6.1%+/-0.2% post-SII, P=0.005) and did not become immunosensitized., Conclusion: Using current protocols, SII in the absence of exenatide results in impressive insulin-independence rates and the durability of insulin independence seems to be promising. However, a beneficial effect of exenatide should not be discounted until tested in randomized controlled studies.
- Published
- 2010
- Full Text
- View/download PDF
11. Histologic graft assessment after clinical islet transplantation.
- Author
-
Toso C, Isse K, Demetris AJ, Dinyari P, Koh A, Imes S, Kin T, Emamaullee J, Senior P, and Shapiro AM
- Subjects
- Adult, Autopsy, Case-Control Studies, Diabetes Mellitus, Type 1 immunology, Diabetes Mellitus, Type 1 pathology, Feasibility Studies, Female, Graft Rejection immunology, Graft Rejection pathology, Humans, Islets of Langerhans immunology, Liver immunology, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, Time Factors, Transplantation, Homologous, Ultrasonography, Interventional, Biopsy, Needle, Diabetes Mellitus, Type 1 surgery, Islets of Langerhans pathology, Islets of Langerhans surgery, Islets of Langerhans Transplantation adverse effects, Liver pathology, Liver surgery
- Abstract
Background: An accurate monitoring would help understanding the fate of islet grafts after transplantation., Methods: This work assessed the feasibility of needle biopsy monitoring after intraportal islet transplantation (n=16), and islet graft morphology was studied with the addition of autopsy samples (n=2). Pancreas autopsy samples from two nondiabetic individuals were used as control., Results: Islet tissue was found in five needle samples (31%). Sampling success was related to size (100% sampling for the four biopsies of 1.8 cm in length or higher, P
- Published
- 2009
- Full Text
- View/download PDF
12. Heparin-bonded central venous catheters do not reduce thrombosis in infants with congenital heart disease: a blinded randomized, controlled trial.
- Author
-
Anton N, Cox PN, Massicotte MP, Chait P, Yasui Y, Dinyari PM, Marzinotto V, and Mitchell LG
- Subjects
- Cross-Sectional Studies, Double-Blind Method, Female, Humans, Infant, Infant, Newborn, Male, Thrombosis blood, Thrombosis diagnostic imaging, Thrombosis epidemiology, Ultrasonography, Catheterization, Central Venous instrumentation, Coated Materials, Biocompatible, Heart Defects, Congenital blood, Heparin, Thrombosis prevention & control
- Abstract
Background: Infants with congenital heart disease who require central venous lines are at increased risk of thrombosis. Heparin-bonded catheters provide protection from thrombotic events in some children. However, heparin-bonded catheters may not be as effective in infants =1 year old because of other potential risk factors (smaller vessel size, longer duration of catheter use). No studies have assessed the benefit of heparin-bonded catheters in such specific high-risk populations. The objective of this study was to assess the efficacy of heparin-bonded catheters for preventing thrombosis in infants aged =1 year with congenital heart disease., Study Design: This study was designed as a randomized, controlled, blinded single-center trial. Infants =1 year old with congenital heart disease requiring a central venous line for clinical care were randomly assigned to receive either a heparin-bonded catheter or a standard non-heparin-bonded catheter. Catheters were visually indistinguishable. The primary outcome was incidences of both silent and clinically noticeable thrombosis confirmed by ultrasound. Ultrasounds were reviewed by a blinded central adjudication committee. Interim analysis was performed after enrollment of 97 patients., Results: Eighty-seven patients were evaluable (41 of the patients were female). Thrombotic events occurred in 17 (42.5%) of 40 patients in the non-heparin-bonded catheter group and in 21 (44.7%) of 47 patients in the heparin-bonded catheters group. The study was stopped when the interim analysis showed convincing evidence for no difference between groups over the alternative hypothesis of 50% risk reduction., Conclusions: Infants with congenital heart disease are at significant risk of both silent and clinically identified thrombosis. There seems to be no advantage in using heparin-bonded catheters in infants =1 year of age.
- Published
- 2009
- Full Text
- View/download PDF
13. Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation.
- Author
-
Toso C, Edgar R, Pawlick R, Emamaullee J, Merani S, Dinyari P, Mueller TF, Shapiro AM, and Anderson CC
- Subjects
- Alemtuzumab, Antibodies, Monoclonal, Humanized, Antilymphocyte Serum, Daclizumab, Female, Flow Cytometry, Humans, Male, Middle Aged, Prospective Studies, Antibodies, Monoclonal pharmacology, Antibodies, Neoplasm pharmacology, Immunoglobulin G pharmacology, Immunosuppressive Agents pharmacology, Islets of Langerhans Transplantation immunology, Lymphocyte Subsets drug effects, Lymphocyte Subsets immunology
- Abstract
This prospective study assessed lymphocyte subsets in the peripheral blood of 42 islet allograft recipients using flow cytometry from 2 weeks and up to 2 years post-transplantation. Subjects received daclizumab (n = 16), Thymoglobulin (n = 12) or alemtuzumab (n = 14). Alemtuzumab was associated with an early (within 1 month) and transient (up to 6 months) increase in the frequency of CD3(+) CD4(+) Foxp3(+) T cells, while daclizumab induced a near complete loss of these cells (P
- Published
- 2009
- Full Text
- View/download PDF
14. Quality of life after islet transplant: impact of the number of islet infusions and metabolic outcome.
- Author
-
Toso C, Shapiro AM, Bowker S, Dinyari P, Paty B, Ryan EA, Senior P, and Johnson JA
- Subjects
- Adult, Female, Humans, Hyperglycemia blood, Male, Surveys and Questionnaires, Treatment Outcome, Islets of Langerhans metabolism, Islets of Langerhans Transplantation, Quality of Life
- Abstract
The health-related quality of life (HRQL; Health Utilities Index Mark 2) and the fear of hypoglycemia (Hypoglycemia Fear Survey) were assessed after islet transplant; the impact of a single islet infusion and of the metabolic outcome were determined. A control group included 166 patients with type 1 diabetes. Islet transplant had no impact on overall HRQL. Prior to transplant, islet recipients had more fear of hypoglycemia than controls (P<0.000001), but this improved up to 36 months after transplant (P<0.00001, pretransplant vs. each time point). With a single islet infusion, this fear improved substantially (P<0.00001), but improved further with subsequent islet infusions (P=0.01). Fear of hypoglycemia correlated with the occurrence of hypoglycemia (r=0.47, P=0.01), and even more so with blood glucose stability (r=0.56, P=0.0007) and insulin requirement (r=0.69, P=0.000002).
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.